Robert Stuart to Infusions, Intravenous
This is a "connection" page, showing publications Robert Stuart has written about Infusions, Intravenous.
Connection Strength
0.319
-
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
Score: 0.114
-
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.
Score: 0.045
-
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
Score: 0.029
-
Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther. 2011 Feb; 28(2):150-9.
Score: 0.022
-
Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics. 2010; 28(3):217-30.
Score: 0.020
-
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21.
Score: 0.020
-
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33.
Score: 0.020
-
Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009 Apr 07; 150(7):455-64.
Score: 0.019
-
Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: rationale/design of Peptic Ulcer Bleed study. Aliment Pharmacol Ther. 2008 Apr; 27(8):666-77.
Score: 0.018
-
High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat. 2000 Aug; 62(3):237-44.
Score: 0.011